Chronic Myeloid Leukemia: Managing Patients After Failure of TKI Therapy
Clinical Focus - Elias Jabbour, MD, provides an overview of state-of-the-art postprogression treatment of CML after 2 previous TKIs. (Source: Clinical Care Options Leukemia)
Source: Clinical Care Options Leukemia - October 27, 2016 Category: Hematology Source Type: research
Diagnosis and Management of Chronic Lymphocytic Leukemia
Learning Module - Jacqueline Barrientos, MD, provides a comprehensive look at current optimal therapy for patients with CLL. (Source: Clinical Care Options Leukemia)
Source: Clinical Care Options Leukemia - October 24, 2016 Category: Hematology Source Type: research
The Promise and Challenges of Minimal Residual Disease Detection in AML
Discussion - MRD testing in AML can identify patients in CR at higher risk of relapse, but there are considerable barriers to using MRD to guide treatment. (Source: Clinical Care Options Leukemia)
Source: Clinical Care Options Leukemia - October 20, 2016 Category: Hematology Source Type: research
Designing a New Approach to Clinical Trials in AML
Discussion - Harry P. Erba, MD, discusses the challenge of, and possible solution for, developing an effective trial for elderly patients with AML who are unfit for chemotherapy. (Source: Clinical Care Options Leukemia)
Source: Clinical Care Options Leukemia - September 28, 2016 Category: Hematology Source Type: research
Acute Leukemias: A Collection of Expert Commentaries
Learning Module - This activity includes a collection of commentaries focused on acute leukemias. Various experts provide practical perspectives on recent treatment advances and everyday clinical challenges. (Source: Clinical Care Options Leukemia)
Source: Clinical Care Options Leukemia - September 27, 2016 Category: Hematology Source Type: research
How I Interpret Clinical Trial Results to Choose Salvage Immunotherapies for Adult Patients With B-Precursor ALL
Discussion - Are you ready to use immunotherapies for your patients with relapsed/refractory ALL? Dan Douer, MD, provides his interpretation of the data and discusses the benefits and risks of different treatments. (Source: Clinical Care Options Leukemia)
Source: Clinical Care Options Leukemia - September 1, 2016 Category: Hematology Source Type: research
Targeting CD33 in AML: Therapeutic Strategies With New Antibody –Drug Conjugates
Learning Module - In this interactive, CME-certified module, William Donnellan, MD, provides expert perspective on advances in CD33-targeted therapies for AML and discusses ongoing clinical trials. (Source: Clinical Care Options Leukemia)
Source: Clinical Care Options Leukemia - August 31, 2016 Category: Hematology Source Type: research
Targeting CD33 in AML: Therapeutic Strategies With New Antibody –Drug Conjugates
Slideset - In this downloadable slideset, William Donnellan, MD, discusses slides illustrating the key data and clinical relevance of anti-CD33 antibodies in the treatment of AML. (Source: Clinical Care Options Leukemia)
Source: Clinical Care Options Leukemia - August 31, 2016 Category: Hematology Source Type: research
Hematologic Malignancies: A Review of Key Clinical Studies
Slideset - John M. Burke, MD; Elias Jabbour, MD; Rami S. Komrokji, MD; and Shaji Kumar, MD, provide an analysis of key presentations on hematologic malignancies from the 2016 clinical oncology meeting in Chicago. (Source: Clinical Care Options Leukemia)
Source: Clinical Care Options Leukemia - August 30, 2016 Category: Hematology Source Type: research
How I Adapt CLL Treatment to Evolving Molecular Considerations
Discussion - How should factors such as del(17q) andIgHV mutations be leveraged to individualize treatment in CLL? (Source: Clinical Care Options Leukemia)
Source: Clinical Care Options Leukemia - August 9, 2016 Category: Hematology Source Type: research
Major Discoveries and the Prospect of Improved Patient Survival in AML and ALL
Discussion - Here is an overview of some new approaches for the treatment of AML and ALL that are showing promise in clinical trials. (Source: Clinical Care Options Leukemia)
Source: Clinical Care Options Leukemia - July 26, 2016 Category: Hematology Source Type: research
Targeting CD123 in AML
Discussion - Targeting CD123 in AML with multiple approaches shows promise as a novel treatment for this challenging disease. (Source: Clinical Care Options Leukemia)
Source: Clinical Care Options Leukemia - June 28, 2016 Category: Hematology Source Type: research
First-line HCVAD + Ponatinib Appears Superior to HCVAD + Dasatinib in Ph+ ALL
Slideset - This propensity score analysis comparing 2 phase II studies shows improved EFS and OS with addition of ponatinib vs dasatinib to standard HCVAD chemotherapy in newly diagnosed Ph+ ALL. (Source: Clinical Care Options Leukemia)
Source: Clinical Care Options Leukemia - June 13, 2016 Category: Hematology Source Type: research
First-line CPX-351 Superior to 7 + 3 Induction in Older Patients With High-Risk AML
Slideset - Randomized phase III investigation of CPX-351 vs “7 + 3” induction identified a potential new standard of care for older patients with previously untreated high-risk AML. (Source: Clinical Care Options Leukemia)
Source: Clinical Care Options Leukemia - June 8, 2016 Category: Hematology Source Type: research
Fractionated Dosing Optimizes CAR T-Cell Therapy in Adult Relapsed/Refractory ALL
Slideset - Fractionated dosing of CTL019 minimized CRS-related toxicity and maintained high response rates in patients with relapsed/refractory CD19+ ALL. (Source: Clinical Care Options Leukemia)
Source: Clinical Care Options Leukemia - June 6, 2016 Category: Hematology Source Type: research
